EG 427

EG 427 is a French biotech company specializing in pinpoint gene therapy using Herpes Simplex Virus 1 for chronic diseases, particularly peripheral nervous disorders. The company's innovative approach leverages HSV-1's unique properties to ensure highly specific and long-lasting transgene expression. Since its establishment in 2019, EG 427 has made significant strides in the biotechnology industry.

In its first operational year, the company successfully developed an exclusive HSV-1 vector platform and demonstrated proof of concept in the treatment of the most common type of neurogenic bladder resulting from supra-sacral spinal cord damage. EG 427 is now actively exploring other possibilities of pinpoint gene therapy for related indications involving different segments of the peripheral nervous system. With a team of renowned experts in HSV-1 vectorology and spinal cord injury-related illnesses, EG 427 plans to launch its inaugural clinical trials by 2023.

The company recently secured a €5.00M Series A investment on 13th July 2023. The successful investment further validates the potential of EG 427's pioneering approach and reinforces its position as a key player in the biotechnology industry.